Aeolus Pharmaceuticals, Inc. recently announced the launch of a Phase 1 study to examine the safety, tolerability, and pharmacokinetics of the company’s treatment for the lung and delayed effects of acute radiation exposure, called AEOL 10150.
The treatment is being developed under a $118.4 million advanced research and development contract with the Biomedical Advanced Research and Development Authority (BARDA). The treatment is also being developed as a treatment for idiopathic pulmonary fibrosis (IPF), and for use with a radiation therapy to treat solid tumors.
“This phase 1 study will give us important safety and pharmacokinetic data that will allow us to accelerate and expand the development of AEOL 10150 in both large commercial and in biodefense indications that represent major unmet medical needs,” Aeolus’ President and CEO John L. McManus said.
Aeolus said the study will expand the safety database for AEOL 10150 and will be the first set of human safety data for the new formulation of the treatment developed under a BARDA contract. The company also said data from the study will be used to support the IPF and radiation therapy indications, in addition to the use of the treatment as a medical countermeasure against exposure from sulfur mustard gas.
The new formulation is significantly cheaper than the prior formulation and is the subject of new patents pending in the United States and other global authorities, according to Aeolus.